Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape
He-Lu Wang, Nan Chi, Hong-Tao Zhang
TL;DR
Bispecific antibodies show promise in treating glioblastoma by targeting both tumor cells and immune cells, improving immune response and overcoming tumor defenses.
Contribution
The paper highlights mechanistic advances and delivery innovations in bispecific antibodies for glioblastoma immunotherapy.
Findings
BsAbs can cross the blood-brain barrier and modulate the immunosuppressive tumor environment.
BsAbs outperform traditional therapies by redirecting immune cells and blocking immune checkpoints.
BsAbs face challenges in delivery efficiency and immune-related adverse events but offer enhanced therapeutic precision.
Abstract
The application of bispecific antibody (BsAbs)-based therapeutic strategies for glioblastoma (GBM) has shown considerable promise. By concurrently targeting tumor-associated antigens and immune effector cells, BsAbs can traverse the blood-brain barrier, modulate the immunosuppressive tumor microenvironment, and surmount challenges such as intratumoral heterogeneity and immune evasion. Accumulating evidence indicates that BsAbs surpass conventional monoclonal antibodies and chimeric antigen receptor T cell therapies in the context of GBM through mechanisms that include the redirection of immune cells, blockade of immune checkpoints, and synergistic inhibition of oncogenic signaling pathways. Although constrained by limitations in intracerebral delivery efficiency and the potential for immune-related adverse events, BsAbs represent a promising new frontier in GBM immunotherapy. They…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMonoclonal and Polyclonal Antibodies Research · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery